MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
41.16
+2.15 (5.51%)
At close: Jun 2, 2025, 4:00 PM
48.99
+7.83 (19.02%)
After-hours: Jun 2, 2025, 7:59 PM EDT
MLTX Employees
MoonLake Immunotherapeutics had 100 employees as of December 31, 2024. The number of employees increased by 50 or 100.00% compared to the previous year.
Employees
100
Change (1Y)
50
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$1,452,065
Market Cap
2.61B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
MLTX News
- 21 days ago - MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 5 weeks ago - MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 - GlobeNewsWire
- 7 weeks ago - MoonLake Immunotherapeutics: A Buy At Dips - Seeking Alpha
- 2 months ago - MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates - GlobeNewsWire
- 3 months ago - MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 4 months ago - MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon - Seeking Alpha
- 5 months ago - MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab - GlobeNewsWire
- 9 months ago - MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 - GlobeNewsWire